These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27216075)

  • 21. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016.
    Ramalheira E; Stone GG
    J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
    Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
    Sader HS; Mendes RE; Pfaller MA; Shortridge D; Flamm RK; Castanheira M
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).
    Castanheira M; Farrell SE; Deshpande LM; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3012-20. PubMed ID: 23587957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
    Zhang H; Liang B; Wang J; Cai Y
    Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.